MUVON Therapeutics Reports Positive 12-Month Phase 2 Follow-up Data Confirming Durable Efficacy of its First-in-Class Muscle Regeneration Therapy in Stress Urinary Incontinence

MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269), ...

Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool

Hotel Blacklist has launched a new free online resource designed to help hotels and accommodation providers identify ...

ASUS Named as One of the Forbes World’s Best Employers for the Tenth Consecutive Year

· ASUS earns recognition on the Forbes World’s Best Employers 2026 list, marking the 10th consecutive year the company has ...